How to rationally use daprostat to treat anemia in patients with chronic kidney disease

Daprodustat, a HIF-PH inhibitor, has been widely studied and used to treat anemia in patients with chronic kidney disease. Its mechanism is different from traditional anemia treatment drugs. It can activate the secretion of endogenous erythropoietin (EPO) by simulating a hypoxic environment, thereby promoting the production of red blood cells. To rationally use dapoxostat to treat anemia caused by chronic kidney disease, you must first ensure the correctness of the indications. Patients with chronic kidney disease often suffer from anemia due to impaired kidney function, resulting in decreased levels of erythropoietin (EPO). In these patients, daprostat helps improve anemia symptoms by promoting the production of EPO.

Reasonable dose adjustment is crucial during treatment. Typically, the initial dose of daprostat is 8 mg per day, with subsequent dose adjustments based on the patient's clinical response and hemoglobin level. The patient's hemoglobin level should be monitored regularly to ensure it remains within the target range. Excessive correction of anemia may lead to adverse reactions such as hypertension and thrombosis, so excessive doses need to be avoided.

Daprostat, as an oral drug, has obvious advantages over traditional erythropoietin (ESA) injection treatment. Especially for patients who require long-term treatment, oral treatment is more convenient and can significantly improve patient compliance. When using daprostat, physicians should consider the patient's condition, especially renal function and other comorbidities. Although daprostat is less dependent on iron stores, in some cases patients may require additional iron supplements to increase therapeutic efficacy.

During the treatment process, doctors need to regularly evaluate the patient's hemoglobin, iron levels and possible side effects, and adjust the treatment plan in a timely manner. Of particular concern is hyperphosphatemia, a side effect that needs to be managed by controlling dietary phosphorus intake or using phosphorus binders. Rational use of dapostat also requires patients to follow the doctor's treatment plan to ensure the continuity of the drug and the effectiveness of the treatment.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat